Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celltrion Inc.

www.celltrion.com/en

Latest From Celltrion Inc.

Two Months To Add Two Words – Biosimilar Supplement Review Times May Be Hindering Uptake

Biosimilar supplement approvals by the US FDA take on average about five months as sponsors request easier and quicker ways to update labels.
Biosimilars Post Market Regulation & Studies

Asia Deal Watch: Antibody-Drug Conjugates Reign With Alliances Involving Celltrion, Miracogen & WuXi Biologics

Celltrion and iProgen will co-develop ADC candidates, Miracogen and Synaffix sign a technology license after a successful research collaboration, and WuXi will provide clinical trial material to NBE Therapeutics.

Deals Commercial

Asia Deal Watch: Takeda On A Deal Spree

Takeda has inked three deals in recent days: a cancer antibody-drug conjugate partnership, a PI3K out-license and a nanomedicine drug-delivery pact. AstraZeneca gains expanded rights to Kyowa Hakko Kirin’s Fasenra.

Asia Pacific Commercial

Big Brands Poised To Lose US Marketing Exclusivity In 2019

With the first generic versions of blockbuster brands like Advair, Lyrica, Restasis and Sensipar and the first biosimilars of Herceptin, Avastin and Rituxan expected to launch in the US, 2019 could be a notable year for generics and biosimilars.

Generic Drugs Market Intelligence
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
    • Generic Drugs
  • Services
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Gastrointestinal
  • Immune Disorders
  • Infectious & Viral Diseases
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Celltrion Inc.
  • Senior Management
  • Hyoung-Ki Kim, Co-CEO
  • Contact Info
  • Celltrion Inc.
    Phone: (82) 32 850 5000
    23 Academy-ro
    Yeonsu-gu
    Incheon City, 406-840
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register